---
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/265804100.md"
description: "Mikael Dolsten, former head of research at Pfizer, stated that he has withdrawn from the election for the board of Novo Nordisk AS for personal reasons"
datetime: "2025-11-13T22:52:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265804100.md)
  - [en](https://longbridge.com/en/news/265804100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265804100.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/265804100.md) | [繁體中文](https://longbridge.com/zh-HK/news/265804100.md)


# 

Mikael Dolsten, former head of research and development at Pfizer, stated that he has withdrawn from the election for the board of Novo Nordisk AS for personal reasons

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)

## 相关资讯与研究

- [BREAKINGVIEWS-Novo Nordisk is Denmark’s big little problem: podcast](https://longbridge.com/zh-CN/news/280570178.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/zh-CN/news/281206892.md)
- [Novo Nordisk A/S Approves Board Changes](https://longbridge.com/zh-CN/news/280694583.md)
- [Novo Nordisk A/S Approves Final Dividend for 2025, Payable in March 2026](https://longbridge.com/zh-CN/news/280694679.md)
- [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/zh-CN/news/281201382.md)